Virologica Sinica, 28 (2) : 71-80, 2013
Review
Human Monoclonal Antibodies as Candidate Therapeutics Against Emerging Viruses and HIV-1
1. Protein Interactions Group, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA

2. Basic Research Program, Science Applications International Corporation-Frederick, Inc., Frederick, Maryland 21702, USA

3. Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA

4. Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430072, China
 Correspondence: gongr@wh.iov.cn;dimiter.dimitrov@nih.gov
(308.98KB)  
Abstract
More than 40 monoclonal antibodies (mAbs) have been approved for a number of disease indications with only one of these (Synagis)-for a viral disease, and not for therapy but for prevention. However, in the last decade novel potent mAbs have been discovered and characterized with potential as therapeutics against viruses of major importance for public health and biosecurity including Hendra virus (HeV), Nipah virus (NiV), severe acute respiratory syndrome coronavirus (SARS-CoV), Ebola virus (EBOV), West Nile virus (WNV), influenza virus (IFV) and human immunodeficiency virus type 1 (HIV-1). Here, we review such mAbs with an emphasis on antibodies of human origin, and highlight recent results as well as technologies and mechanisms related to their potential as therapeutics.
  Accepted: 21 Feb 2013  Published online: 5 Apr 2013
Home |  Resources |  About Us |  Support |  Contact Us |  Privacy |  Powered by CanSpeed | 
Copyright © 2015 Virologica Sinica. All rights reserved